October 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Dainippon Sumitomo Pharma Licenses Precursor of Norepinephrine to Chelsea Therapeutics International
 

Tokyo, June 5, 2006 (JCN) - Dainippon Sumitomo Pharma has signed a licensing agreement with US pharmaceutical company Chelsea Therapeutics International.

Under the agreement terms, Chelsea Therapeutics International will receive exclusive rights to develop and sell Dops, Dainippon Sumitomo Pharma's proprietary agent, worldwide except in Japan, China, South Korea and Taiwan.

In Japan, Dops, which is a precursor of norepinephrine, is currently available for the treatment of frozen gait and dizziness associated with Parkinson's disease, and vertigo, dizziness and fatigue associated with orthostatic hypotension in hemodialysis patients.

Going forward, Chelsea Therapeutics International will develop the agent as an orphan drug for the treatment of orthostatic hypotension associated with autonomic disorder.


By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Dainippon Sumitomo News  
  Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S.  (Oct 10, 2013)
  Dainippon Sumitomo Pharma Opens Subsidiary in Singapore  (Jan 22, 2013)
  Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent  (Dec 28, 2012)
  NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area  (Oct 23, 2008)
  Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug  (May 8, 2008)
  Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic  (Dec 13, 2006)
  Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent  (Nov 28, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs  (July 26, 2006)



 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)